



FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

Date:- February 05, 2026

To,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400 001.

BSE Script Code: 531599

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,

Bandra-Kurla Complex, Bandra (E),

Mumbai - 400 051.

NSE Symbol: FDC

Sub: Press Release on Q3 - FY 2025-26 Results.

Dear Sir/Ma'am,

Please find attached herewith a Press Release issued in relation to the Unaudited Consolidated Financial Results of the Company for the Quarter and months ended December 31, 2025.

Kindly take the same on record.

Thanking you,

Yours truly

For FDC Limited

Varsharani Katre

Company Secretary & Legal Head

Membership No.: FCS-8948

FDC Limited announces Q3 FY26 results

Mumbai, February 5, 2026: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) has announced its financial results for the third quarter and nine months ended December 31, 2025.

Consolidated Financial Results for Q3 FY26 and 9M FY26:

(Rs. in crores)

Particulars	Q3 FY26	Q3 FY25	Y-o-Y Grw %	9M FY26	9M FY25	Y-o-Y Grw %
Revenue from operations	465	464	0.1%	1,586	1,616	-1.9%
EBITDA	52	47	12.1%	226	269	-15.8%
EBITDA Margin	11.2%	10.1%		14.3%	16.6%	
PBT (before exceptional items)	57	51	11.7%	255	304	-16.1%
PBT (after exceptional items)	36	51	-28.9%	234	304	-22.9%
PAT	28	37	-23.6%	178	228	-22.0%
EPS (Rs.)	1.74	2.28	-23.6%	10.93	14.02	-22.0%

Commenting on the results:

Q3 FY26 revenue from operations stood at Rs. 465 crores, registering a marginal growth of 0.1% Y-o-Y, primarily impacted by lower sales in the Domestic Formulations business. Export Formulations business delivered strong growth of 55.0% Y-o-Y, while the API business declined by 17.0% Y-o-Y. For 9M FY26, revenue from operations stood at Rs. 1,586 crores with a de-growth of 1.9%.

The US business continues to show steady recovery, with earlier challenges largely addressed. During 9M FY26 revenue from supplies stood at Rs. 43 crores reflecting a Y-o-Y growth of 82.8%, driven by improved execution and demand momentum. Overall US business revenue grew 2.1% Y-o-Y, despite a lower profit share (impacted due to recall) from the US partners. Excluding this recall impact, the underlying performance of the US business remains strong and on an improved trajectory.

Our EBITDA for Q3 FY26 stood at Rs. 52 crores, with margins at 11.2% compared to 10.1% last year. EBITDA margin improvement driven by higher gross margin and enhanced operational efficiencies.

Business Segment-wise Sales Performance

(Rs. in crores)

Particulars	Q3 FY26	Y-o-Y Grw %	9M FY26	Y-o-Y Grw%
Revenue from Operations	465	0.1%	1,586	-1.9%
Domestic Formulations	369	-5.2%	1,329	-2.5%
Export Formulations (US)	25	199.1%	55	2.1%
Export Formulations (Non-US)	46	23.2%	117	4.2%
APIs	23	-17.0%	79	-3.2%

Domestic Formulations:

Domestic Formulations sales stood at Rs. 369 crores for Q3 FY26, reflecting a de-growth of 5.2% Y-o-Y. For the nine months of FY26, Domestic Formulations sales were Rs. 1,329 crores, registering a de-growth of 2.5% compared to the corresponding period last year, due to lower sales in our top brands like Zifi, Electral and Enerzal. Domestic Formulations business contributed 80% to total consolidated sales during the quarter and 84% for 9M FY26.

According to the secondary sales data by IQVIA (MAT December 31, 2025), the Company recorded a 4.8% growth. Electral continued to strengthen its market position, rising to 18th rank in the IPM (MAT December 31, 2025) from 20th in the same period last year.

Export Formulations:

Export Formulations sales stood at Rs. 71 crores in Q3 FY26, registering a growth of 55.0% Y-o-Y, contributing 15% to company's consolidated sales. For the nine months of FY26, Export Formulations sales were Rs. 172 crores, reflecting a 3.8% growth compared to the same period last year. Export Formulations performance has improved consistently over the last 2-3 quarters, supported by improved supplies and better execution across focused markets.

During the quarter, the Company received U.S. FDA approval for Pilocarpine Ophthalmic Solution 1%, 2% and 4%, strengthening FDC's ophthalmic portfolio and reinforcing its commitment to expanding its presence in the regulated markets.

APIs:

API business registered sales of Rs. 23 crores in Q3 FY26, down by 17.0% Y-o-Y and accounted for 5% of total consolidated sales. During 9M FY26, the API business de-grew by 3.2% registering sales of Rs. 79 crores.

ABOUT FDC LTD

FDC was established in the year 1936 as a partnership firm. This firm was incorporated as a Company in 1940, with the vision of building a world-class company while contributing to making the nation self-reliant in healthcare. To cite a few, FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE. FDC is a forerunner in the manufacturing and marketing of Oral Rehydration Salts (ORS), anti-infectives and ophthalmic. FDC has also set up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs) as well as Finished Dosage Formulations. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life for millions globally.

Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve several risks and uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.